evidence: Tumour-specific survival in the IL-2 group and the control group was 98 vs 81% after 1 year and 86 vs 73% after 5 years (P=0.04)
intervention: preoperative administration of interleukin-2 (IL-2)
comparator: immunomonitoring without immunomodulation
outcome: Tumour-specific survival after 5 years